382 related articles for article (PubMed ID: 11967950)
1. Generation of monoclonal antibodies specific for human kallikrein 2 (hK2) using hK2-expressing tumors.
Fisher TL; Nocera M; Willis RA; Turner MJ; Abdul Alim CS; Brown DM; Bourne PA; di Sant'Agnese PA; Messing EM; Lord EM; Frelinger JG
Prostate; 2002 May; 51(3):153-65. PubMed ID: 11967950
[TBL] [Abstract][Full Text] [Related]
2. Cross-reactivity of ten anti-prostate-specific antigen monoclonal antibodies with human glandular kallikrein.
Corey E; Buhler KR; Vessella RL
Urology; 1997 Oct; 50(4):567-71; discussion 571-2. PubMed ID: 9338733
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific human kallikrein (hK2) as a novel marker for prostate cancer.
Young CY; Seay T; Hogen K; Charlesworth MC; Roche PC; Klee GG; Tindall DJ
Prostate Suppl; 1996; 7():17-24. PubMed ID: 8950360
[TBL] [Abstract][Full Text] [Related]
4. Expression of human glandular kallikrein, hK2, in mammalian cells.
Kumar A; Goel AS; Hill TM; Mikolajczyk SD; Millar LS; Kuus-Reichel K; Saedi MS
Cancer Res; 1996 Dec; 56(23):5397-402. PubMed ID: 8968092
[TBL] [Abstract][Full Text] [Related]
5. Expression of human prostate-specific glandular kallikrein protein (hK2) in the breast cancer cell line T47-D.
Hsieh ML; Charlesworth MC; Goodmanson M; Zhang S; Seay T; Klee GG; Tindall DJ; Young CY
Cancer Res; 1997 Jul; 57(13):2651-6. PubMed ID: 9205072
[TBL] [Abstract][Full Text] [Related]
6. Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments.
Väisänen V; Peltola MT; Lilja H; Nurmi M; Pettersson K
Anal Chem; 2006 Nov; 78(22):7809-15. PubMed ID: 17105175
[TBL] [Abstract][Full Text] [Related]
7. Identification of human glandular kallikrein hK2 from LNCaP cells.
Grauer LS; Charlesworth MC; Saedi MS; Finlay JA; Liu RS; Kuus-Reichel K; Young CY; Tindall DJ
J Androl; 1996; 17(4):353-9. PubMed ID: 8889697
[TBL] [Abstract][Full Text] [Related]
8. Characterization of monoclonal antibodies against prostate specific antigen produced by genetic immunization.
Leinonen J; Niemelä P; Lövgren J; Bocchi L; Pettersson K; Nevanlinna H; Stenman UH
J Immunol Methods; 2004 Jun; 289(1-2):157-67. PubMed ID: 15251421
[TBL] [Abstract][Full Text] [Related]
9. Structural comparison of prostate-specific antigen and human glandular kallikrein using molecular modeling.
Bridon DP; Dowell BL
Urology; 1995 May; 45(5):801-6. PubMed ID: 7538242
[TBL] [Abstract][Full Text] [Related]
10. The presence of prostate-specific antigen-related genes in primates and the expression of recombinant human prostate-specific antigen in a transfected murine cell line.
Karr JF; Kantor JA; Hand PH; Eggensperger DL; Schlom J
Cancer Res; 1995 Jun; 55(11):2455-62. PubMed ID: 7538903
[TBL] [Abstract][Full Text] [Related]
11. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells.
Veveris-Lowe TL; Lawrence MG; Collard RL; Bui L; Herington AC; Nicol DL; Clements JA
Endocr Relat Cancer; 2005 Sep; 12(3):631-43. PubMed ID: 16172196
[TBL] [Abstract][Full Text] [Related]
12. Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes.
Shariat SF; Roudier MP; Wilcox GE; Kattan MW; Scardino PT; Vessella RL; Erdamar S; Nguyen C; Wheeler TM; Slawin KM
Cancer Res; 2003 Aug; 63(15):4662-70. PubMed ID: 12907647
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug.
Janssen S; Rosen DM; Ricklis RM; Dionne CA; Lilja H; Christensen SB; Isaacs JT; Denmeade SR
Prostate; 2006 Mar; 66(4):358-68. PubMed ID: 16302271
[TBL] [Abstract][Full Text] [Related]
14. Measurement of prostate-specific antigen and human glandular kallikrein 2 in different body fluids.
Lövgren J; Valtonen-André C; Marsal K; Lilja H; Lundwall A
J Androl; 1999; 20(3):348-55. PubMed ID: 10386814
[TBL] [Abstract][Full Text] [Related]
15. Detection of human glandular kallikrein, hK2, as its precursor form and in complex with protease inhibitors in prostate carcinoma serum.
Grauer LS; Finlay JA; Mikolajczyk SD; Pusateri KD; Wolfert RL
J Androl; 1998; 19(4):407-11. PubMed ID: 9733142
[TBL] [Abstract][Full Text] [Related]
16. Kininogenase activity of prostate-derived human glandular kallikrein (hK2) purified from seminal fluid.
Charlesworth MC; Young CY; Miller VM; Tindall DJ
J Androl; 1999; 20(2):220-9. PubMed ID: 10232657
[TBL] [Abstract][Full Text] [Related]
17. Free and total human glandular kallikrein 2 in patients with prostate cancer.
Väisänen V; Pettersson K; Alanen K; Viitanen T; Nurmi M
Urology; 2006 Jul; 68(1):219-25. PubMed ID: 16844459
[TBL] [Abstract][Full Text] [Related]
18. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer.
Stephan C; Jung K; Nakamura T; Yousef GM; Kristiansen G; Diamandis EP
Int J Urol; 2006 Mar; 13(3):238-43. PubMed ID: 16643616
[TBL] [Abstract][Full Text] [Related]
19. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
Scorilas A; Plebani M; Mazza S; Basso D; Soosaipillai AR; Katsaros N; Pagano F; Diamandis EP
Prostate; 2003 Feb; 54(3):220-9. PubMed ID: 12518327
[TBL] [Abstract][Full Text] [Related]
20. Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma.
Diamandis EP; Okui A; Mitsui S; Luo LY; Soosaipillai A; Grass L; Nakamura T; Howarth DJ; Yamaguchi N
Cancer Res; 2002 Jan; 62(1):295-300. PubMed ID: 11782391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
